Cost-effectiveness of preventing type-2-diabetes mellitus in Germany;Kosteneffektivität der nichtmedikamentösen prävention des typ 2 diabetes mellitus in Deutschland

Gesundheitsokonomie und Qualitatsmanagement

Volumn 14, Issue 2, 2009, Pages 71-75

  Schaufler, T M ^a  

^a Emil Heckel   (Germany)

Author keywords

Cost effectiveness; Cost utility analysis; Diabetes mellitus; Prevention

Indexed keywords

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; GERMANY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; MONTE CARLO METHOD; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE;

EID: 63449096472     PISSN: 14322625     EISSN: 14394049     Source Type: Journal    
DOI: 10.1055/s-2008-1027778     Document Type: Article

References (24)

1. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Genf: World Health Organization, 1999
2. Schaufler TM. Volkswirtschaftlicher Nutzen medizinischer Frühdiag-nostik. Hamburg: Verlag Dr. Kovac, 2007
3. Rathmann W, Haastert B, Icks A et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003; 46:182-189
4. Sterbetafel 2002/2004 In: Statistisches Bundesamt (Hrsg). Wiesbaden: Statistisches Bundesamt, 2005
5. Harris MI, Klein R, Welborn TA et al. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992; 15: 815-819
6. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 2002; 346: 393-403
7. Coffey JT, Brandle M, Zhou H et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002; 25: 2238-2243
8. Herman WH, Hoerger TJ, Brandle M et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Annals of internal medicine 2005; 142: 323-332
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 1998; 352: 837-853
10. Dolben J, Owens D, Young S et al. Retinopathy at presentation in type 2 (non-insulindependent) diabetic patients. Diabetic Medicine 1988; 5: 20
11. Aldington SJ, Kohner EM, Nugent A. Retinopathy at entry in the United Kingdom prospective diabetes study (UKPDS) of maturity onset diabetes. Diabetic Medicine 1987; 4: 355
12. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? U.K. prospective diabetes study 61. Diabetes Care 2002; 25:1410-1417
13. Löwel H, Stieber J, Koenig W et al. Das Diabetes-bedingte Herzinfarkt-risiko in einer süddeutschen Bevölkerung-Ergebnisse der MONICA-Augsburg-Studien 1985-1994. Diabetologie und Stoffwechsel 1999; 8: 11-21
14. Liebl A, Neiss A, Spannheimer A et al. Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany-Results from the CODE-2 study. Experimental and clinical endocrinology & diabetes 2002; 110:10-16
15. Kaarisalo MM, Raiha I, Sivenius J et al. Diabetes worsens the outcome of acute ischemic stroke. Diabetes research and clinical practice 2005; 69: 293-298
16. Deutsche Stiftung Organtransplantation. Organtransplantationen in Deutschland einschließblich Lebendspender-Transplantation. Deutsche Stiftung Organtransplantation 2006; http://www.dso.de/grafiken/g29.html,Zugriff am 13.07. 2006
17. Frei U, Schober-Halstenberg H. Nierenersatztherapie in Deutschland. Berlin: QuaSi-Niere gGmbH, 2004
18. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes (UKPDS 64). Kidney international 2003; 63: 225-232
19. Romming Sorensen V, Schwartz Sorensen S, Feldt-Rasmussen B. Long-term graft and patient survival following renal transplantation in diabetic patients. Scandinavian journal of urology and nephrology 2006; 40: 247-251
20. Shearer A, Scuffham P, Gordois A et al. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U. S. Diabetes Care 2003; 26: 2305-2310
21. Liebl A, Neiss A, Spannheimer A et al. Kosten des Typ-2-Diabetes in Deutschland. Ergebnisse der CODE-2-Studie. Dtsch Med Wochenschr 2001; 126: 585-589
22. Weber C, Neeser K, Wenzel H et al. Cost of type 2 diabetes in Germany over 8 years-The ROSSO study No. 2. Journal of Medical Economics 2006; 9: 45-53
23. Kolominsky-Rabas PL, Heuschmann PU, Marschall D et al. Lifetime Cost of Ischemic Stroke in Germany: Results and National Projections From a Population-Based Stroke Registry. The Erlangen Stroke Project. Stroke 2006; 37: 1179-1183
24. Nagel E, Niechzial M. Bewertung chirurgischer Therapien: angemessen - notwendig - zweckmäßig. Berlin: Springer, 1999; XIV: 148